CRISPR Stock Future Price Prediction


USD 78.66  1.20  1.55%   

CRISPR Therapeutics stock price prediction is an act of determining the future value of CRISPR Therapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of CRISPR Therapeutics' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of CRISPR Therapeutics and does not consider all of the tangible or intangible factors available from CRISPR Therapeutics' fundamental data. We analyze noise-free headlines and recent hype associated with CRISPR Therapeutics AG, which may create opportunities for some arbitrage if properly timed.
Continue to CRISPR Therapeutics Basic Forecasting Models to cross-verify your projections.
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of CRISPR Therapeutics based on different types of headlines from major news networks to social media. The CRISPR stock price prediction module provides an analysis of price elasticity to changes in media outlook on CRISPR Therapeutics over a specific investment horizon.
EPS Estimate Next Quarter
EPS Estimate Current Year
EPS Estimate Next Year
Wall Street Target Price
EPS Estimate Current Quarter
Quarterly Revenue Growth YOY
Using CRISPR Therapeutics hype-based prediction, you can estimate the value of CRISPR Therapeutics AG from the perspective of CRISPR Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards CRISPR Therapeutics using CRISPR Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards CRISPR using crowd psychology based on the activity and movement of CRISPR Therapeutics' stock price.
CRISPR Therapeutics Enterprise Value over EBIT is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Enterprise Value over EBIT of 13.00. As of 12th of August 2022, Enterprise Value over EBITDA is likely to grow to 13.50, while Current Ratio is likely to drop 19.30.

CRISPR Therapeutics Short Interest

A significant increase or decrease in CRISPR Therapeutics' short interest from the previous month could be a good indicator of investor sentiment towards CRISPR. Short interest can provide insight into the potential direction of CRISPR Therapeutics stock and how bullish or bearish investors feel about the market overall. An investor who is long CRISPR Therapeutics may also wish to track short interest. As short interest increases, investors should be becoming more worried about CRISPR Therapeutics and may potentially protect profits, hedge CRISPR Therapeutics with its derivative instruments, or be ready for some potential downside.
200 Day MA
Short Percent
Short Ratio
Shares Short Prior Month
11.5 M
50 Day MA
Shares Short
11 M

CRISPR Therapeutics Hype to Price Pattern

Investor biases related to CRISPR Therapeutics' public news can be used to forecast risks associated with investment in CRISPR. The trend in average sentiment can be used to explain how an investor holding CRISPR can time the market purely based on public headlines and social activities around CRISPR Therapeutics AG. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of CRISPR Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about CRISPR Therapeutics.

CRISPR Therapeutics Implied Volatility

CRISPR Therapeutics' implied volatility exposes the market's sentiment of CRISPR Therapeutics AG stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if CRISPR Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that CRISPR Therapeutics stock will not fluctuate a lot when CRISPR Therapeutics' options are near their expiration.
This module is based on analyzing investor sentiment around taking a position in CRISPR Therapeutics. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in CRISPR Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying CRISPR because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

CRISPR Therapeutics after-hype prediction price

  $ 82.63  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.

Prediction based on Rule 16 of the current CRISPR contract

Based on the Rule 16, the options market is currently suggesting that CRISPR Therapeutics AG will have an average daily up or down price movement of about 7.51% per day over the life of the 2022-08-12 option contract. With CRISPR Therapeutics trading at $78.66, that is roughly $5.91. If you think that the market is fully incorporating CRISPR Therapeutics' daily price movement you should consider acquiring CRISPR Therapeutics AG options at the current volatility level of 120.16%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of CRISPR Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of CRISPR Therapeutics in the context of predictive analytics.
LowReal ValueHigh
LowNext ValueHigh
16 Analysts
LowTarget PriceHigh
Estimates (10)
LowProjected EPSHigh
Please note, it is not enough to conduct a financial or market analysis of a single entity such as CRISPR Therapeutics. Your research has to be compared to or analyzed against CRISPR Therapeutics' peers to derive any actionable benefits. When done correctly, CRISPR Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in CRISPR Therapeutics.

CRISPR Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of CRISPR Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in CRISPR Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many smart people who confused the symmetrical distributions of stock prices, such as prices of CRISPR Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

CRISPR Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting CRISPR Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on CRISPR Therapeutics' historical news coverage. CRISPR Therapeutics' after-hype downside and upside margins for the prediction period are 77.72 and 87.54, respectively. We have considered CRISPR Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value 78.66
After-hype Price
CRISPR Therapeutics is very steady asset. Analysis and calculation of next after-hype price of CRISPR Therapeutics is based on 3 months time horizon.

CRISPR Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a company such as CRISPR Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CRISPR Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with CRISPR Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
 0.80  4.91  3.97   0.05  6 Events / Month0 Events / MonthIn about 6 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility

CRISPR Therapeutics Hype Timeline

CRISPR Therapeutics is currently traded for 78.66. The entity has historical hype elasticity of 3.97 and average elasticity to hype of competition of 0.05. CRISPR is projected to increase in value after the next headline with price projected to jump to 82.63 or above. The average volatility of media hype impact on the company stock price is about 98.99%. The price boost on the next news is forecasted to be 5.05% whereas the daily expected return is currently at 0.8%. The volatility of related hype on CRISPR Therapeutics is about 8183.33% with expected price after next announcement by competition of 78.71. CRISPR Therapeutics AG currently holds about 2.22 B in cash with 504.4 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 28.68. Given the investment horizon of 90 days the next projectedpress releasewill be in about 6 days.
Continue to CRISPR Therapeutics Basic Forecasting Models to cross-verify your projections.

CRISPR Therapeutics Related Hype Analysis

Having access to credible news sources related to CRISPR Therapeutics' direct competition is more important than ever and may enhance your ability to predict CRISPR Therapeutics' future price movements. Getting to know how CRISPR Therapeutics rivals react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how CRISPR Therapeutics may potentially react to the hype associated with one of its peers.

CRISPR Therapeutics Additional Predictive Modules

Most predictive techniques to examine CRISPR price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for CRISPR using various technical indicators. When you analyze CRISPR charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About CRISPR Therapeutics Predictive Indicators

The successful prediction of CRISPR Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as CRISPR Therapeutics AG, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of CRISPR Therapeutics based on analysis of CRISPR Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to CRISPR Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to CRISPR Therapeutics's related companies.

Story Coverage note for CRISPR Therapeutics

The number of cover stories for CRISPR Therapeutics depends on current market conditions and CRISPR Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that CRISPR Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about CRISPR Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

CRISPR Therapeutics Short Properties

CRISPR Therapeutics' future price predictability will typically decrease when CRISPR Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of CRISPR Therapeutics AG often depends not only on the future outlook of the potential CRISPR Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. CRISPR Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Shares Percent Shares Out14.88%
Short Percent Of Float17.25%
Float Shares76.32M
Shares Short Prior Month10.64M
Average Daily Volume Last 10 Day1.27M
Average Daily Volume In Three Month1.99M
Date Short Interest15th of July 2022
Continue to CRISPR Therapeutics Basic Forecasting Models to cross-verify your projections. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.